The pediatric preclinical testing program: Description of models and early testing results-Reference-Cited by-同舟云学术

The pediatric preclinical testing program: Description of models and early testing results

Published:2006-10-25 Issue:7 Volume:49 Page:928-940
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatr. Blood Cancer

Author:

Houghton Peter J.¹,Morton Christopher L.¹,Tucker Chandra¹,Payne Debbie¹,Favours Edward¹,Cole Claire¹,Gorlick Richard²,Kolb E. Anders²,Zhang Wendong²,Lock Richard³,Carol Hernan³,Tajbakhsh Mimi³,Reynolds C. Patrick⁴,Maris John M.⁵,Courtright Joshua⁵,Keir Stephen T.⁶,Friedman Henry S.⁶,Stopford Charles⁶,Zeidner Joseph⁶,Wu Jianrong¹,Liu Tiebin¹,Billups Catherine A.¹,Khan Javed⁷,Ansher Sherry⁸,Zhang Jian⁸,Smith Malcolm A.⁸

Affiliation:

1. St. Jude Children's Research Hospital, Memphis, Tennessee

2. The Children's Hospital at Montefiore, Bronx, New York

3. Children's Cancer Institute Australia for Medical Research, Randwick, New South Wales, Australia

4. Children's Hospital of Los Angeles, Los Angeles, California

5. Children's Hospital of Philadelphia, University of Pennsylvania School of Medicine and Abramson Family Cancer Research Institute, Philadelphia, Pennsylvania

6. Duke University Medical Center, Durham, North Carolina

7. Pediatric Oncology Branch, Oncogenomics Section, National Cancer Institute (NCI), Bethesda, Maryland

8. Cancer Therapy Evaluation Program, NCI, Bethesda, Maryland

Funder

National Cancer Institute

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology and Child Health

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pbc.21078

Reference39 articles.

1. ReisLA PercyCL BuninGR.Cancer incidence and survival among children and adoloescents. United States SEER Program 1975–1995. NIH (Pub. No. 99–4649. Volume Introduction—SEER Pediatric Monograph. National Cancer Institute Bethesda MD;1999. pp1–15.

2. GurneyJG YoungJL RoffersSD et al.Cancer incidence and survival among children and adolescents: United States SEER Program 1975–1995 NIH (Pub. 99‐4649). National Cancer Institute SEER Program1999.111–124.

3. Phase II testing of melphalan in children with newly diagnosed rhabdomyosarcoma: a model for anticancer drug development.

4. Experimental chemotherapy of human medulloblastoma cell lines and transplantable xenografts with bifunctional alkylating agents;Friedman HS;Cancer Res,1988

Cited by 410 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Whole genome and reverse protein phase array landscapes of patient derived osteosarcoma xenograft models;Scientific Reports;2024-08-27

2. Preclinical models for the study of pediatric solid tumors: focus on bone sarcomas;Frontiers in Oncology;2024-07-18

3. Roadmap for the next generation of Children’s Oncology Group rhabdomyosarcoma trials;Cancer;2024-06-28

4. Synergistic Antitumor Activity of Talazoparib and Temozolomide in Malignant Rhabdoid Tumors;Cancers;2024-05-28

5. Assessment of Patient-Derived Xenograft Growth and Antitumor Activity: The NCI PDXNet Consensus Recommendations;Molecular Cancer Therapeutics;2024-04-19